Home
Search
Search Only:

Search Keyword data

Total: 50 results found.

Page 1 of 3
... increases with the number of monthly infusions that he or she receives. The most recent data update translates to a rate of 1.35 cases per 1,000 for patients on the drug for a year or longer, but rises ...
... subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. ...
... the data, and they certainly did not write the papers or control publication. Grants were at arm?s length. Thanks to the academy?s increasing dependence on industry, that distance is a thing of the past. ...
... betas and Copaxone (glatiramer acetate, Teva) says independent analyst Datamonitor. The Russian approval of Merck Serono's Movectro (oral cladribine) is a landmark in the treatment for relapsing-remitting ...
5. NHS 'to undergo radical overhaul'
(News/MS General News)
... this, a new body, HealthWatch, will be set up to compile data on performance, while GP boundaries will be abolished to allow patients to register with any doctor they want. Mr Lansley also announced he ...
... of AT1Ra and treatment with an inhibitor of TSP-1. These data suggest that AT1R antagonists, frequently prescribed as antihypertensives, may be useful to interrupt this proinflammatory, CNS-specific ...
... PhD, presented data from the first 500 participants in the projected 1,700-subject study. He reported that 56% of MS patients, 43% of those with other neurologic illnesses, and 22% of healthy volunteers ...
... This is further attested to by the failure of large epidemiological studies to show an associa¬tion between MS and other autoimmune disorders. These significant data seem to have been ignored by some ...
... reactive astrocytes in the vicinity of the lesions are derived from preexisting FGFR3-expressing cells, likely to be astrocytes. These data resolve a long-running debate about the origins of the main ...
... on the drug, combined with data on how many total patients are receiving treatment. “That’s the best way for people to visualize what’s going on,” Mullen says. “The whole communications strategy around ...
... rates in a comparator dataset, modified for patients receiving treatment by multiplying by the hazard ratio derived separately for each disease modifying treatment from the randomised trials. Results ...
... and safety data from pivotal Betaferon clinical trials, along with findings from a single-arm study designed to demonstrate the efficacy and safety of Betaferon among Chinese patients with relapsing-remitting ...
... after data was presented at the European Committee for Treatment and Research in Multiple Sclerosis congress in Dusseldorf, Germany, in September. In January, Merck said four patients were diagnosed ...
... drugs. "The Innovation Pass pilot will help collect the essential data needed to demonstrate that such drugs, which would not otherwise be available to patients, are making a big difference to their ...
... 2009, 60,700 people have used Tysabri worldwide. Although the absolute risk for PML in patients treated with Tysabri cannot be precisely determined, the sponsor has now released data suggesting that the ...
Avanir Pharmaceuticals, Inc. announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies ...
... of neurology and vice chairman for clinical practice at Indiana University School of Medicine, agreed that he was optimistic for the agent’s approval. Cost concerns remain since the safety data on Fampridine-SR ...
... company declines to quantify the risk based on current data, using the absolute method it applied in April, the rate would come out to one in 5,140 -- or 11 of the 56,500 patients who have taken the drug ...
...  According to data supplied by the German Multiple Sclerosis Society’s national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone ...
...  We performed a population-based case-control study in Gothenburg that included 509 MS cases and 2,067 controls, born 1959-1986. Data on infections and vaccinations were obtained from questionnaires ...
«StartPrev123NextEnd»